GAITHERSBURG, Md., July 19 /PRNewswire/ -- Panacea Pharmaceuticals,
Inc. today announced the appointments of Steven A. Fuller, Ph.D. as Vice
President, Product Development, and Billie Jo Wood as Director, Clinical
Laboratory Services. Dr. Fuller will direct preclinical product
development, validation, process development, and manufacturing for the
Company's therapeutic and diagnostic products, in collaboration with staff
in regulatory affairs and clinical development. Ms. Wood will assume
responsibility for managing Panacea Laboratories, a division of Panacea
Pharmaceuticals, including testing of patient samples, assuring adherence
to regulatory requirements, and marketing the availability of the Company's
diagnostic tests.
"We are very pleased to add Steve and Billie Jo to the team at
Panacea", commented Stephen N. Keith, MD, MSPH, President and Chief
Operating Officer at Panacea Pharmaceuticals. "Steve brings a wealth of
experience in the development and manufacturing of a range of therapeutic
and diagnostic products. And Billie Jo has considerable experience managing
a clinical laboratory at one of the leading academic medical centers.
Panacea is continuing to strengthen its senior management team as we
aggressively pursue our therapeutic and diagnostic product development
efforts."
Dr. Fuller has over 23 years of experience in the pharmaceutical and
biotechnology industries working on a range of therapeutic and diagnostic
products. Most recently Dr. Fuller served as Vice President, Product and
Process Development at Nabi Biopharmaceuticals, Inc. While at Nabi, he held
positions of increasing responsibility including Senior Director, Product
Development and Product Development Director. At ADI Diagnostics, Dr.
Fuller was a Senior Research Scientist, Program Manager and Director of
Operations; ADI Diagnostics is a diagnostics manufacturer and distributor
specializing in cancer and infectious disease assays. He is an author of
numerous peer- reviewed publications and one patent. Dr. Fuller received
his B.S. degree in Biology from Wheaton College and his Ph.D. in genetics
from Michigan State University. He is a member of the American Society for
Microbiology and the American Association for Laboratory Animal Science.
Prior to joining Panacea, Ms. Wood worked as a Laboratory Coordinator
at the Johns Hopkins University Medical Center, supervising technicians and
providing staff consultation to ensure accurate performance of tests and
reporting test results in compliance with the Clinical Laboratory
Improvement Amendments of 1988 and the Joint Commission on Accreditation of
Healthcare Organizations regulations. Ms. Wood has experience utilizing
polymerase chain reaction, gel electrophoresis, cell culture,
microimmuno-fluorescence, and nucleic acid amplification. She received her
Bachelor of Science in Biology from York College of Pennsylvania, and a
Masters of Science in Biotechnology and a MBA from Johns Hopkins.
About Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical
company focused on the development and commercialization of therapeutics
and diagnostics for diseases with substantial, unmet clinical needs. The
Company's product development strategy is based on novel therapeutic agents
and approaches for cancer treatment, as well as acute and chronic
neurodegenerative conditions, such as hypoxia-induced neurological insult,
Parkinson's Disease, and Alzheimer's disease. Panacea has an extensive
patent portfolio covering its neurodegenerative and oncology technologies.
More information about the Company is available at
http://www.PanaceaPharma.com.
Except for historical information presented in this press release,
matters discussed herein may constitute "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995.
Forward- looking statements are based on the opinions and estimates of
management only as of the date of this release and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from any future results, performance, or achievements expressed
or implied by such statements. Factors that might cause such a difference
include, but are not limited to, uncertainties related to our access to
capital, the progress, costs, and results of any clinical trials undertaken
by us, progress of our research and development projects, and uncertainties
related to whether our product candidates would ultimately achieve
commercial success. We do not undertake any obligation to update publicly
any forward-looking statement, whether as a result of new information,
future events, or otherwise unless required by law.
SOURCE Panacea Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panaceapharma.com/
CONTACT:
Stephen N. Keith, MD, MSPH, President & COO
of Panacea Pharmaceuticals, Inc., +1-240-243-8000, or fax
+1-240-465-0450, skeith@panaceapharma.com
|
